Introduction: Biodegradable Temporizing Matrix (BTM) is a new synthetic dermal substitute suitable for wound closure and tissue regeneration. The data in paediatric population remain limited. The study purpose is to review the indications for BTM application in paediatric patients, evaluate the short-term and long-term results, including complications and functional outcomes, as well as to share some unique observations regarding the use of BTM in paediatric population. Patients and Methods: Patients undergoing reconstructive surgery and BTM application during the last three years were included. Data collected included patient demographics, primary diagnosis, previous surgical management, post-operative complications and final outcomes. BTM was used in 32 patients. The indications varied including epidermolysis bullosa (n = 6), burns (n = 4), trauma (n = 7), infection (n = 4), ischemia or necrosis (n = 11). Results: The results were satisfying with acceptable aesthetic and functional outcomes. Complications included haematoma underneath the BTM leading to BTM removal and re-application (n = 1), BTM infection (n = 1) and split-thickness skin graft failure on top of BTM requiring re-grafting (n = 2). Conclusions: BTM can be a good alternative to large skin grafts, locoregional flaps or even free flaps. The big advantages over other dermal substitutes or skin grafts are that BTM is less prone to infection and offers excellent scarring by preserving the normal skin architecture. Specifically in children, BTM might not require grafting, resulting in spontaneous healing with good scarring. In critically ill patients, BTM reduces the operation time and there is no donor site morbidity. BTM should be considered in the reconstructive ladder when discussing defect coverage options in children and young people.

Background/Objectives: The purpose of this study is to review the use of Biodegradable Temporizing Matrix (BTM) for releasing finger webspaces and flexion contractures in recessive dystrophic epidermolysis bullosa (RDEB) in paediatric patients and evaluate the short-term and mid-term results. Methods: Patients who underwent release of webspace fusion and flexion contractures followed by BTM application during the last two years (2022–2024) were included. The data collected included the patient demographics, previous surgical management, type of release, post-operative complications and final outcomes. BTM was used in four patients. Results: The functional outcomes were acceptable but temporary, as three cases required or are planned for re-operation due to recurrence. Conclusion: The surgical experience using BTM as a single-stage dressing/dermal substitute in hand surgery for paediatric RDEB has shown feasibility and safety regarding infection rates. To the best of our knowledge, this is the first reported study regarding the BTM use for releasing hands in epidermolysis bullosa.